Evidence map›Paper›PMID 38559188›Full record

ArticlebioRxiv : the preprint server for biology2024

An engineered human cardiac tissue model reveals contributions of systemic lupus erythematosus autoantibodies to myocardial injury.

Sharon Fleischer, Trevor R Nash, Manuel A Tamargo, Roberta I Lock, Gabriela Venturini, Margaretha Morsink, Vanessa Li, Morgan J Lamberti, Pamela L Graney, Martin Liberman and 10 more

Open access · greenAbstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Sharon FleischerDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Trevor R NashDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Manuel A TamargoDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Roberta I LockDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Gabriela VenturiniDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Margaretha MorsinkDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Vanessa LiDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Morgan J LambertiDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Pamela L GraneyDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Martin LibermanDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Youngbin KimDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Richard Z ZhuangDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Jaron WhiteheadDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Richard A FriedmanBiomedical Informatics Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Rajesh K SoniProteomics and Macromolecular Crystallography Shared Resource, Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.ORCID 0000-0002-4556-4358
Jonathan G SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Christine E SeidmanDepartment of Genetics, Harvard Medical School, Boston, MA, USA.
Laura Geraldino-PardillaDepartment of Medicine, Columbia University, New York, NY, USA.
Robert WinchesterDepartment of Medicine, Columbia University, New York, NY, USA.
Gordana Vunjak-NovakovicDepartment of Biomedical Engineering, Columbia University, New York, NY, USA.
Columbia University · USHarvard University · USBrigham and Women's Hospital · USColumbia University Irving Medical Center · US

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Tissue Engineering Resource Center: TTDP41EB027062 · NIBIB · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Gordana Vunjak-Novakovic · 2019 to 2026
$12.6M
Engineering Vascularized Cardiac MuscleR01HL076485 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Gordana Vunjak-Novakovic · 2005 to 2026
$9.2M
NCI NIH HHS P30 CA013696NHLBI NIH HHS R01 HL076485NIBIB NIH HHS P41 EB027062
6 · The paper itself

Abstract

Systemic lupus erythematosus (SLE) is a highly heterogenous autoimmune disease that affects multiple organs, including the heart. The mechanisms by which myocardial injury develops in SLE, however, remain poorly understood. Here we engineered human cardiac tissues and cultured them with IgG fractions containing autoantibodies from SLE patients with and without myocardial involvement. We observed unique binding patterns of IgG from two patient subgroups: (i) patients with severe myocardial inflammation exhibited enhanced binding to apoptotic cells within cardiac tissues subjected to stress, and (ii) patients with systolic dysfunction exhibited enhanced binding to the surfaces of viable cardiomyocytes. Functional assays and RNA sequencing (RNA-seq) revealed that IgGs from patients with systolic dysfunction exerted direct effects on engineered tissues in the absence of immune cells, altering tissue cellular composition, respiration and calcium handling. Autoantibody target characterization by phage immunoprecipitation sequencing (PhIP-seq) confirmed distinctive IgG profiles between patient subgroups. By coupling IgG profiling with cell surface protein analyses, we identified four pathogenic autoantibody candidates that may directly alter the function of cells within the myocardium. Taken together, these observations provide insights into the cellular processes of myocardial injury in SLE that have the potential to improve patient risk stratification and inform the development of novel therapeutic strategies.

Indexed as

Autoantibodiesautoimmune diseasecardiac tissue engineeringmyocardial inflammationsystemic lupus erythematosus

Identifiers

PMID38559188
PMCPMC10979865
OpenAlexW4392683546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.